About us

ChemomAb specializes in the development of proprietary monoclonal antibodies, directed towards novel targets, for the treatment of immune-mediated and fibrotic disorders including orphan indications. Read More

Research & Development

ChemomAb identified a novel chemokine pathway that mediates inflammation and fibrosis and developed proprietary antibodies that target it. Compelling data has been gathered on the efficacy of our lead compound in the orphan disease. Read More


ChemomAb to present “CM-101, a novel CCL24 blocking monoclonal antibody ameliorates hepatic injury in NASH induced mouse model” at AASLD’s Liver Meetingֲ® 2017 Read More